Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era: A Meta-analysis

Yen Chien Lee, Chung Cheng Hsieh, Yen Ling Lee, Chung-Yi Li

Research output: Contribution to journalReview article

Abstract

Molecular markers are important in guiding treatment and predicting outcome in the genomic era. Meta-analysis of molecular markers in myelofibrosis through a search of PubMed and Medline through October 31, 2017 was performed. Markers with more than 3 studies that compared overall survival (OS) and leukemia-free survival (LFS) were analyzed. A total of 16 studies were included. Hazard ratios (HRs) for OS were as follows: IDH 2.65 (95% confidence interval [CI], 1.66-4.21), SRSF2 2.12 (95% CI, 1.18-3.79), high-risk myeloma 2.11 (95% CI, 1.70-2.61), ASXL1 1.92 (95% CI, 1.60-2.32), EZH2 1.88 (95% CI, 1.32-2.67), JAK2 1.41 (95% CI, 1.04-1.93) in the univariate analysis and 1.49 (95% CI, 0.42-5.30) in the multivariate analysis. LFS of JAK2 and SRSF2 had HRs of 1.81 (95% CI, 0.42-5.30) and 0.36 (95% CI, 0.02-6.48), respectively. In conclusion, mutations in IDH, SRSF2, and ASXL1 had worse prognosis in OS with HRs around 2. JAK2 and SRSF2 mutation were not associated with increased leukemia transformation. The adverse effect of triple-negative, which was often compared with CALR mutation, needs to be explored.

Original languageEnglish
Pages (from-to)558-568
Number of pages11
JournalClinical Lymphoma, Myeloma and Leukemia
Volume18
Issue number9
DOIs
Publication statusPublished - 2018 Sep 1

Fingerprint

Primary Myelofibrosis
Meta-Analysis
Confidence Intervals
Leukemia
Mutation
PubMed
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Lee, Yen Chien ; Hsieh, Chung Cheng ; Lee, Yen Ling ; Li, Chung-Yi. / Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era : A Meta-analysis. In: Clinical Lymphoma, Myeloma and Leukemia. 2018 ; Vol. 18, No. 9. pp. 558-568.
@article{e81435aecb254587bb5253c5bfdcfb17,
title = "Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era: A Meta-analysis",
abstract = "Molecular markers are important in guiding treatment and predicting outcome in the genomic era. Meta-analysis of molecular markers in myelofibrosis through a search of PubMed and Medline through October 31, 2017 was performed. Markers with more than 3 studies that compared overall survival (OS) and leukemia-free survival (LFS) were analyzed. A total of 16 studies were included. Hazard ratios (HRs) for OS were as follows: IDH 2.65 (95{\%} confidence interval [CI], 1.66-4.21), SRSF2 2.12 (95{\%} CI, 1.18-3.79), high-risk myeloma 2.11 (95{\%} CI, 1.70-2.61), ASXL1 1.92 (95{\%} CI, 1.60-2.32), EZH2 1.88 (95{\%} CI, 1.32-2.67), JAK2 1.41 (95{\%} CI, 1.04-1.93) in the univariate analysis and 1.49 (95{\%} CI, 0.42-5.30) in the multivariate analysis. LFS of JAK2 and SRSF2 had HRs of 1.81 (95{\%} CI, 0.42-5.30) and 0.36 (95{\%} CI, 0.02-6.48), respectively. In conclusion, mutations in IDH, SRSF2, and ASXL1 had worse prognosis in OS with HRs around 2. JAK2 and SRSF2 mutation were not associated with increased leukemia transformation. The adverse effect of triple-negative, which was often compared with CALR mutation, needs to be explored.",
author = "Lee, {Yen Chien} and Hsieh, {Chung Cheng} and Lee, {Yen Ling} and Chung-Yi Li",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.clml.2018.06.004",
language = "English",
volume = "18",
pages = "558--568",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "9",

}

Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era : A Meta-analysis. / Lee, Yen Chien; Hsieh, Chung Cheng; Lee, Yen Ling; Li, Chung-Yi.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 18, No. 9, 01.09.2018, p. 558-568.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era

T2 - A Meta-analysis

AU - Lee, Yen Chien

AU - Hsieh, Chung Cheng

AU - Lee, Yen Ling

AU - Li, Chung-Yi

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Molecular markers are important in guiding treatment and predicting outcome in the genomic era. Meta-analysis of molecular markers in myelofibrosis through a search of PubMed and Medline through October 31, 2017 was performed. Markers with more than 3 studies that compared overall survival (OS) and leukemia-free survival (LFS) were analyzed. A total of 16 studies were included. Hazard ratios (HRs) for OS were as follows: IDH 2.65 (95% confidence interval [CI], 1.66-4.21), SRSF2 2.12 (95% CI, 1.18-3.79), high-risk myeloma 2.11 (95% CI, 1.70-2.61), ASXL1 1.92 (95% CI, 1.60-2.32), EZH2 1.88 (95% CI, 1.32-2.67), JAK2 1.41 (95% CI, 1.04-1.93) in the univariate analysis and 1.49 (95% CI, 0.42-5.30) in the multivariate analysis. LFS of JAK2 and SRSF2 had HRs of 1.81 (95% CI, 0.42-5.30) and 0.36 (95% CI, 0.02-6.48), respectively. In conclusion, mutations in IDH, SRSF2, and ASXL1 had worse prognosis in OS with HRs around 2. JAK2 and SRSF2 mutation were not associated with increased leukemia transformation. The adverse effect of triple-negative, which was often compared with CALR mutation, needs to be explored.

AB - Molecular markers are important in guiding treatment and predicting outcome in the genomic era. Meta-analysis of molecular markers in myelofibrosis through a search of PubMed and Medline through October 31, 2017 was performed. Markers with more than 3 studies that compared overall survival (OS) and leukemia-free survival (LFS) were analyzed. A total of 16 studies were included. Hazard ratios (HRs) for OS were as follows: IDH 2.65 (95% confidence interval [CI], 1.66-4.21), SRSF2 2.12 (95% CI, 1.18-3.79), high-risk myeloma 2.11 (95% CI, 1.70-2.61), ASXL1 1.92 (95% CI, 1.60-2.32), EZH2 1.88 (95% CI, 1.32-2.67), JAK2 1.41 (95% CI, 1.04-1.93) in the univariate analysis and 1.49 (95% CI, 0.42-5.30) in the multivariate analysis. LFS of JAK2 and SRSF2 had HRs of 1.81 (95% CI, 0.42-5.30) and 0.36 (95% CI, 0.02-6.48), respectively. In conclusion, mutations in IDH, SRSF2, and ASXL1 had worse prognosis in OS with HRs around 2. JAK2 and SRSF2 mutation were not associated with increased leukemia transformation. The adverse effect of triple-negative, which was often compared with CALR mutation, needs to be explored.

UR - http://www.scopus.com/inward/record.url?scp=85049338389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049338389&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2018.06.004

DO - 10.1016/j.clml.2018.06.004

M3 - Review article

C2 - 29970342

AN - SCOPUS:85049338389

VL - 18

SP - 558

EP - 568

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 9

ER -